MediWound (MDWD) CMO details options and RSU awards in Form 3 filing
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
MediWound Ltd.’s Chief Medical Officer, Ety Klinger, filed an initial Form 3 showing equity holdings in ordinary shares, stock options, and restricted share units. The filing lists multiple option grants to buy ordinary shares, including 3,571 underlying shares at an exercise price of 36.0500 that expire on December 31, 2028, and 5,491 underlying shares at 12.2500 that expire on April 23, 2030, along with several later-dated grants through March 4, 2036.
Footnotes describe RSU awards granted on February 15, 2023, February 26, 2024, February 11, 2025, and March 4, 2026, each vesting 25% on the first anniversary of grant and 6.25% quarterly over the following three years. The filing also records direct holdings of ordinary shares in several line items.
Positive
- None.
Negative
- None.
Insider Trade Summary
13 transactions reported
Mixed
13 txns
Insider
Klinger Ety
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy ordinary shares) — 3,571 shares (Direct);
Ordinary shares — 1,743 shares (Direct)
Footnotes (1)
- The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on February 15, 2023 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The options reported in this row were granted to the Reporting Person on May 16, 2022 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The options reported in this row were granted to the Reporting Person on February 15, 2023 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The options reported in this row were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The options reported in this row were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
FAQ
What does MediWound (MDWD) Chief Medical Officer Ety Klinger report on this Form 3?
Ety Klinger reports her initial ownership in MediWound equity, including ordinary shares, stock options, and restricted share units. The form details several option grants with specified exercise prices and expiration dates, plus RSUs with multi-year vesting schedules, giving a structured view of her compensation-linked holdings.
What stock options does Ety Klinger hold in MediWound (MDWD)?
The Form 3 lists several stock option grants to buy MediWound ordinary shares at fixed exercise prices. Examples include options over 3,571 underlying shares at 36.0500 expiring December 31, 2028, and 5,491 underlying shares at 12.2500 expiring April 23, 2030, plus additional grants extending to 2036.
How do Ety Klinger’s MediWound (MDWD) RSU awards vest?
The RSUs generally vest 25% on the first anniversary of the grant date, then 6.25% each quarter over the following three years. This applies to RSUs granted on February 15, 2023, February 26, 2024, February 11, 2025, and March 4, 2026, creating a four-year vesting timeline.
Are there any buy or sell transactions in this MediWound (MDWD) Form 3?
No buy or sell transactions are reported. The Form 3 functions as an initial statement of beneficial ownership, listing existing holdings in stock options, RSUs, and ordinary shares. The transaction summary shows no purchases, sales, exercises, gifts, or tax-withholding events recorded in this filing.
What are the expiration dates of Ety Klinger’s MediWound (MDWD) options?
The options expire on various future dates tied to each grant, including December 31, 2028, April 23, 2030, March 4, 2031, May 16, 2032, February 15, 2033, February 26, 2034, February 11, 2035, and March 4, 2036.